In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli

2019 Fleischmann, 2020, In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic Gram-negative bacilli, Antimicrob Agents Chemother, 64, e01711, 10.1128/AAC.01711-19 Lee, 2016, Clinical usefulness of arbekacin, Infect Chemother, 48, 1, 10.3947/ic.2016.48.1.1 Hamada, 2011, Clinical efficacy of arbekacin for Gram-negative bacteria, J Infect Chemother, 17, 876, 10.1007/s10156-011-0262-x 2020 Plazomicin – Injection Sader, 2015, Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia, Antimicrob Agents Chemother, 59, 3263, 10.1128/AAC.04839-14 Zapor, 2010, In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center, Antimicrob Agents Chemother, 54, 3015, 10.1128/AAC.01173-09 Brion, 1984, Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits, Antimicrob Agents Chemother, 25, 168, 10.1128/AAC.25.2.168 Dube, 2018, A multicentre, open label, randomized, comparative, parallel group, active-controlled, phase III clinical trial to evaluate safety and efficacy of arbekacin sulphate injection versus vancomycin injection in patients diagnosed with MRSA infection, J Assoc Phys India, 66, 47